AAG
TAK icon

Armstrong Advisory Group’s Takeda Pharmaceutical TAK Stock Holding History

Armstrong Advisory Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25
Closed -$387 – 985
2025
Q2 		$387 Hold
25
– – ﹤0.01% 906
2025
Q1 		$331 Hold
25
– – ﹤0.01% 828
2024
Q4 		$331 Hold
25
– – ﹤0.01% 828
2024
Q3 		$356 Hold
25
– – ﹤0.01% 770
2024
Q2 		$324 Hold
25
– – ﹤0.01% 779
2024
Q1 		$357 Hold
25
– – ﹤0.01% 755
2023
Q4 		$357 Buy
+25
New +$355 ﹤0.01% 755

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Armstrong Advisory Group's TAK Position: Q3 2025 in Review

Armstrong Advisory Group sold out of Takeda Pharmaceutical (TAK) in Q3 2025, closing a stake of 25 shares — an estimated $387 sold.

Armstrong Advisory Group first reported a position in TAK in Q4 2023 and held it in 7 quarters. The position peaked at $387 in Q2 2025. 329 funds tracked by Wall St. Rank hold TAK as of Q3 2025.

  • Armstrong Advisory Group reported no remaining Takeda Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Armstrong Advisory Group sold 25 Takeda Pharmaceutical shares in Q3 2025, an estimated $387.
  • Armstrong Advisory Group first reported a position in Takeda Pharmaceutical in Q4 2023 and held it in 7 quarters.
  • Armstrong Advisory Group's Takeda Pharmaceutical position peaked at $387 in Q2 2025.
  • 329 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q3 2025.

Based on Armstrong Advisory Group's 13F filing for Q3 2025, filed 8 Oct 2025.